Biophytis / Key word(s): Annual ResultsBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives 07-Apr-2022 / 08:00 CET/CESTBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives Success of Nasdaq IPO in February 2021 €23.9M o.
(0.28)
Summary of operational events (more details are provided in the corresponding press releases available on Biophytis s website: www.biophytis.com)
Launch of the Phase 2-3 COVA study in patients with severe respiratory manifestation of COVID-19
In May 2020, Biophytis received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP), to proceed with its clinical development program COVA, a two-part study assessing Sarconeos (BIO101) in patients aged 45 and older, hospitalized with severe respiratory manifestations following COVID-19 infection;
Biophytis received approvals for COVA from the UK Medicines Healthcare Products Regulatory Agency (MHRA) in June 2020, from the United States Food and Drug Administration (FDA) and the French Health Authority (ANSM) in July 2020 and the Brazilian Health Regulatory Agency (ANVISA) in August 2020;
Biophytis Reports 2020 Full Year Results apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market - Feb 15, 2021 - read this article along with other careers information, tips and advice on BioSpace